SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 36.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,231 shares of the exchange traded fund’s stock after buying an additional 5,629 shares during the quarter. PNC Financial Services Group Inc.’s holdings in SPDR S&P Biotech ETF were worth $2,021,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in XBI. Assetmark Inc. grew its stake in SPDR S&P Biotech ETF by 271,147.4% in the 2nd quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock worth $120,321,000 after acquiring an additional 1,263,547 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of SPDR S&P Biotech ETF by 159.3% during the second quarter. SG Americas Securities LLC now owns 977,702 shares of the exchange traded fund’s stock valued at $93,067,000 after purchasing an additional 600,603 shares in the last quarter. CI Investments Inc. bought a new position in shares of SPDR S&P Biotech ETF during the first quarter valued at approximately $52,366,000. JPMorgan Chase & Co. boosted its stake in shares of SPDR S&P Biotech ETF by 64.5% during the first quarter. JPMorgan Chase & Co. now owns 1,462,600 shares of the exchange traded fund’s stock valued at $128,314,000 after purchasing an additional 573,431 shares in the last quarter. Finally, Howard Capital Management boosted its stake in shares of SPDR S&P Biotech ETF by 557.2% during the second quarter. Howard Capital Management now owns 151,047 shares of the exchange traded fund’s stock valued at $14,378,000 after purchasing an additional 128,065 shares in the last quarter.

NYSEARCA XBI opened at $89.50 on Tuesday. SPDR S&P Biotech ETF has a 52-week low of $78.46 and a 52-week high of $101.55.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 26th. Stockholders of record on Monday, September 24th were paid a dividend of $0.0726 per share. The ex-dividend date of this dividend was Friday, September 21st. This is an increase from SPDR S&P Biotech ETF’s previous quarterly dividend of $0.06. This represents a $0.29 dividend on an annualized basis and a dividend yield of 0.32%.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: Beta

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply